In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii. 2016

Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Emerging resistance to colistin in clinical Acinetobacter baumannii isolates is of growing concern. Since current treatment options for these strains are extremely limited, we investigated the in vitro activities of various antimicrobial combinations against colistin-resistant A. baumannii Nine clinical isolates (8 from bacteremia cases and 1 from a pneumonia case) of colistin-resistant A. baumannii were collected in Asan Medical Center, Seoul, South Korea, between January 2010 and December 2012. To screen for potential synergistic effects, multiple combinations of two antimicrobials among 12 commercially available agents were tested using the multiple-combination bactericidal test (MCBT). Checkerboard tests were performed to validate these results. Among the 9 colistin-resistant strains, 6 were pandrug resistant and 3 were extensively drug resistant. With MCBT, the most effective combinations were colistin-rifampin and colistin-teicoplanin; both combinations showed synergistic effect against 8 of 9 strains. Colistin-aztreonam, colistin-meropenem, and colistin-vancomycin combinations showed synergy against seven strains. Colistin was the most common constituent of antimicrobial combinations that were active against colistin-resistant A. baumannii Checkerboard tests were then conducted in colistin-based combinations. Notably, colistin-rifampin showed synergism against all nine strains (100%). Both colistin-vancomycin and colistin-teicoplanin showed either synergy or partial synergy. Colistin combined with another β-lactam agent (aztreonam, ceftazidime, or meropenem) showed a relatively moderate effect. Colistin combined with ampicillin-sulbactam, tigecycline, amikacin, azithromycin, or trimethoprim-sulfamethoxazole demonstrated limited synergism. Using MCBT and checkerboard tests, we found that only colistin-based combinations, particularly those with rifampin, glycopeptides, or β-lactams, may confer therapeutic benefits against colistin-resistant A. baumannii.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D003091 Colistin Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. Polymyxin E,Colimycin,Colisticin,Colistin Sulfate,Coly-Mycin,Totazina,Sulfate, Colistin
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077731 Meropenem A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid,Merrem,Penem,Ronem,SM 7338,SM-7338,SM7338
D000151 Acinetobacter Infections Infections with bacteria of the genus ACINETOBACTER. Mimae Infections,Infections, Acinetobacter,Infections, Mimae,Acinetobacter Infection,Infection, Acinetobacter,Infection, Mimae,Mimae Infection
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001398 Aztreonam A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. Az-threonam,Azactam,Azthreonam,SQ-26,776,Urobactam,Az threonam,SQ 26,776,SQ26,776

Related Publications

Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
January 2022, PloS one,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
April 2014, International journal of antimicrobial agents,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
October 2016, Diagnostic microbiology and infectious disease,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
February 2012, International journal of antimicrobial agents,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
January 2023, Antibiotics (Basel, Switzerland),
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
April 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
May 2022, Scientific reports,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
April 2024, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
March 2012, Journal of medical microbiology,
Seongman Bae, and Min-Chul Kim, and Su-Jin Park, and Hee Sueng Kim, and Heungsup Sung, and Mi-Na Kim, and Sung-Han Kim, and Sang-Oh Lee, and Sang-Ho Choi, and Jun Hee Woo, and Yang Soo Kim, and Yong Pil Chong
March 2007, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!